SI-BONE to Unveil Third Quarter Financial Results
SI-BONE, Inc. (NASDAQ: SIBN), a leader in addressing sacropelvic disorders, is set to share its financial results for the third quarter of 2025. This announcement is highly anticipated among investors and industry professionals alike.
Conference Call Details
The financial results will be disclosed after market close on a designated day in November. Following the release, management will host a conference call to discuss the outcomes and answer queries from analysts and investors. The call is scheduled to begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. This provides a valuable opportunity for interested stakeholders to gain insights directly from the company’s leadership.
How to Access the Call
Those wishing to participate in the conference call can register in advance through the company’s platform. Additionally, live audio of the event will be accessible through the Investors section of the SI-BONE website. For convenience, the webcast will also be archived, allowing anyone who missed the live broadcast to catch up later. This archived version will be available for at least 90 days, ensuring extensive access to the information shared during the event.
About SI-BONE, Inc.
SI-BONE specializes in innovative technologies designed for the surgical treatment of sacropelvic disorders. The company has made significant strides since it pioneered minimally invasive SI joint surgery in 2009 with the introduction of the iFuse Implant System. To date, SI-BONE has empowered over 4,600 physicians to perform nearly 130,000 procedures, fostering a strong commitment to enhancing patient care in this specialized field.
Clinical Evidence and Research
One of the notable aspects of SI-BONE's offerings is the robust body of clinical evidence supporting its technologies. The company boasts more than 175 peer-reviewed publications, including four randomized controlled trials. This weight of evidence not only validates the effectiveness of SI-BONE's innovations but also positions it as a trusted leader in the minimally invasive surgery sector.
Expansion into Adjacent Markets
Beyond its foundational innovations, SI-BONE has expanded its reach into related markets. By leveraging its expertise in minimally invasive SI joint fusion, the company has begun to market novel solutions in areas such as adult deformity corrections and spinopelvic fixation. This diversification reflects SI-BONE's commitment to addressing a broader range of patient needs and enhancing surgical outcomes.
Contact Information
For further inquiries about SI-BONE or its products, including detailed information on associated risks and benefits, interested parties are encouraged to visit the official SI-BONE website. The company prioritizes transparent communication and is more than willing to provide additional information on its innovative solutions.
Frequently Asked Questions
What is the purpose of SI-BONE's upcoming financial report?
The report will outline the company's financial performance for the third quarter of 2025, providing insights into its overall health and growth trends.
How can I join the conference call?
Interested individuals can register for the conference call through the company's web platform prior to the event.
What technologies does SI-BONE specialize in?
SI-BONE's primary focus is on developing surgical treatments for sacropelvic disorders, including innovations such as the iFuse Implant System.
How has SI-BONE supported physicians?
SI-BONE equips over 4,600 physicians with the necessary tools and training to conduct surgical procedures effectively, leading to nearly 130,000 successful operations.
Where can I find more information about SI-BONE?
Additional information can be found on SI-BONE's official website, which contains comprehensive details about its products and clinical studies.
